C&G Editor in Chief, Erin Harris

  1. Emerging Technologies For Cell Therapy Manufacturing 4/7/2025

    This summary of the Cell & Gene Live, Emerging Technologies in Cell Therapy Manufacturing, explains why automation, robotics, AI, and digital tools offer a clear path to scalable, efficient, and patient-centric manufacturing.

  2. Collaboration Leads To CGT Progress At Astellas' West Coast Innovation Center 3/13/2025

    Yoshi Shitaka, outgoing CSO and Richard Wilson, SVP, Primary Focus Lead (Genetic Regulation) at Astellas share how the company's West Coast Innovation Center serves as a central hub for AI, digital transformation, and more.

  3. Tessera Therapeutics Advances In Vivo Gene Therapy For SCD 1/30/2025

    Tessera Therapeutics' CSO, Michael Holmes, Ph.D., shares information on the company's Gene Writers for sickle cell disease (SCD) and how their work has garnered investment from of the Bill & Melinda Gates Foundation to support their efforts.

  4. 2025 Outlook For CGT: Focus On Non-Oncology Indications, In Vivo Gene Editing, And POC 12/4/2024

    Leaders from Kiji Therapeutics, Precision Biosciences, and Orgenesis weigh in on what will likely accelerate the development of novel treatments, potentially revolutionizing patient care across a wider range of diseases and bringing the promise of personalized medicine closer to reality in 2025 and beyond.

  5. CD70 & Autoimmune Diseases 11/26/2024

    Allogene Therapeutics' Dr. Zachary Roberts shares the clinical-stage biotech's rationale behind selecting CD70 as a target for activated T cells in autoimmune diseases.

  6. Neogene's Focus On Off-The-Shelf TCR Therapies 10/31/2024

    This recap of Episode 87 of Cell & Gene: The Podcast shares Neogene Therapeutics' Carsten Linnemann, Ph.D.'s take on why "off-the-shelf" will make t-cell receptor therapies more accessible to patients.

  7. Highlights From ARM's 2024 Meeting On The Mesa 10/25/2024

    ARM's 2024 Meeting on the Mesa has concluded. Here are a few brief highlights from this year's conference.

  8. Global Regulatory Challenges Of Rare Diseases 9/26/2024

    ISCT's Chief Regulatory Officer, Dr. Bambi Grilley, shares insights from the 2024 Global Regulatory Summit.

  9. Mammoth Biosciences On Epigenetic Editing 8/29/2024

    In case you missed it, this is a summary of Cell & Gene: The Podcast Episode 81 featuring Mammoth Biosciences' Lucas Harrington.

  10. Gamma-Delta T-Cell Therapy for AML 8/29/2024

    William Ho, CEO at IN8bio, shares the company’s progress with gamma-delta T-cell-based immunotherapies and why they represent a groundbreaking approach in oncology, including treatment for Acute Myeloid Leukemia (AML).